[1] Hasegawa K, Fujii S, Matsumoto S, et al.YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation[J]. J Pathol, 2021, 253(1): 80-93. [2] Melo BAC, Vilar LG, Oliveira NR, et al.Human papillomavirus infection and oral squamous cell carcinoma-a systematic review[J]. Braz J Otorhinolaryngol, 2021, 87(3): 346-352. [3] Yoshimoto S, Morita H, Matsuda M, et al.NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment[J]. Lab Invest, 2021, 101(1): 38-50. [4] DeLucia DC, Cardillo TM, Ang L, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer[J]. Clin Cancer Res, 2021, 27(3): 759-774. [5] 陈立智, 胡军, 傅厚丰, 等. L1细胞黏附分子在结肠癌中表达的临床意义和生物学作用[J]. 实用医学杂志, 2020, 36(19): 2690-2695. [6] Srichinthu KK, Kumar GS, Prasad H, et al.Expression of epithelial glycoprotein (EGP40) in oral epithelial dysplasia and oral squamous cell carcinoma (OSCC)[J]. Indian J Dent Res, 2020, 31(5): 738-742. [7] Yu Z, Jiang X, Qin L, et al.A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination[J]. Oncogene, 2021, 40(5): 1027-1042. [8] Wu B, Chang N, Xi H, et al.PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer[J]. Theranostics, 2021, 11(7): 3150-3166. [9] 许立霞, 付强, 胡明星, 等. 活化激酶C受体1对胆管癌细胞迁移和侵袭能力的影响[J]. 中华实验外科杂志, 2021, 38(6): 1079-1081. [10] 中华口腔医学会口腔颌面外科专业委员会肿瘤学组. 口腔颌面部恶性肿瘤治疗指南[J]. 中国口腔颌面外科杂志, 2010, 3(7): 395-403. [11] Shojaeian S, Moazeni-Roodi A, Allameh A, et al.Methylation of TGM-3 promoter and its association with oral squamous cell carcinoma (OSCC)[J]. Avicenna J Med Biotechnol, 2021, 13(2): 65-73. [12] Yang J, Isaji T, Zhang G, et al.EpCAM associates with integrin and regulates cell adhesion in cancer cells[J]. Biochem Biophys Res Commun, 2020, 522(4): 903-909. [13] Gong X, Tang H, Yang K.PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex[J]. Cell Death Dis, 2021, 12(3): 276-291. [14] Buoso E, Masi M, Racchi M, et al.Endocrine-disrupting chemicals' (EDCs) effects on tumour microenvironment and cancer progression: emerging contribution of RACK1[J]. Int J Mol Sci, 2020, 21(23): 9229-9232. [15] Lopez-Nunez O, Ranganathan S.Immunohistochemical expression analysis of EpCAM in hepatoblastomas[J]. Appl Immunohistochem Mol Morphol, 2020, 28(9): 711-718. [16] Dan H, Liu S, Liu J, et al.RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-κB pathway in oral squamous cell carcinoma[J]. Mol Oncol, 2020, 14(4): 795-807. |